On Feb. 26, 2013, the U.S. Food and Drug Administration (FDA) approved Osphena (ospemifene) to treat women with moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy caused by menopause. Read more.
FDA approves Osphena for postmenopausal women with dyspareunia
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.